2023
Cannabis use disorder and adverse cardiovascular outcomes: A population‐based retrospective cohort analysis of adults from Alberta, Canada
Bahji A, Hathaway J, Adams D, Crockford D, Edelman E, Stein M, Patten S. Cannabis use disorder and adverse cardiovascular outcomes: A population‐based retrospective cohort analysis of adults from Alberta, Canada. Addiction 2023, 119: 137-148. PMID: 37766508, DOI: 10.1111/add.16337.Peer-Reviewed Original ResearchConceptsCVD eventsRisk ratioIncident CVDPopulation-based retrospective cohort analysisPopulation-based retrospective cohort studyAdverse cardiovascular disease (CVD) eventsAdverse cardiovascular disease outcomesAdverse CVD eventsGreater risk ratioIncident CVD eventsRetrospective cohort studyAdverse cardiovascular outcomesCardiovascular disease eventsRetrospective cohort analysisCardiovascular disease outcomesMental health comorbiditiesTime of presentationAdministrative health databasesHealth service usePrescription medication useCannabis use disorderMantel-Haenszel techniqueHealth care servicesPoisson regression modelsYear of birthContingency management with stepped care for unhealthy alcohol use among individuals with HIV: Protocol for a randomized controlled trial
Edelman E, Dziura J, Deng Y, DePhilippis D, Fucito L, Ferguson T, Bedimo R, Brown S, Marconi V, Goetz M, Rodriguez-Barradas M, Simberkoff M, Molina P, Weintrob A, Maisto S, Paris M, Justice A, Bryant K, Fiellin D. Contingency management with stepped care for unhealthy alcohol use among individuals with HIV: Protocol for a randomized controlled trial. Contemporary Clinical Trials 2023, 131: 107242. PMID: 37230168, PMCID: PMC10460633, DOI: 10.1016/j.cct.2023.107242.Peer-Reviewed Original ResearchMeSH KeywordsAlcohol DrinkingCohort StudiesCOVID-19HIV InfectionsHumansPandemicsRandomized Controlled Trials as TopicConceptsUnhealthy alcohol useLong-term abstinenceAlcohol useContingency managementAlcohol consumptionFormal alcohol treatmentShort-term abstinenceMotivational enhancement therapyGOV IDENTIFIERSecondary outcomesWeek 24Primary outcomeWeek 12Preliminary efficacyTreatment trialsPhysician managementEfficacy trialsMedical conditionsAlcohol treatmentExploratory outcomesEnhancement therapyAbstinenceTrialsCareHealthy activitiesFactors Associated with Bothersome Symptoms in Individuals With and Without HIV Who Report Alcohol Use
Bahji A, Gordon K, Crystal S, Satre D, Wiliams E, Edelman E, Justice A. Factors Associated with Bothersome Symptoms in Individuals With and Without HIV Who Report Alcohol Use. AIDS And Behavior 2023, 27: 2455-2462. PMID: 36622487, PMCID: PMC10225332, DOI: 10.1007/s10461-022-03972-3.Peer-Reviewed Original Research
2022
Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, Tetrault J, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Network Open 2022, 5: e2246604. PMID: 36515952, PMCID: PMC9856353, DOI: 10.1001/jamanetworkopen.2022.46604.Peer-Reviewed Original ResearchMeSH KeywordsAlcoholismAntiviral AgentsCohort StudiesHepacivirusHepatitis CHepatitis C, ChronicHumansMaleMiddle AgedConceptsCurrent alcohol use disorderLow-risk drinkingAlcohol use disorderVeterans Health AdministrationHistory of AUDDAA treatmentAlcohol use categoriesAUD historyCohort studyRisk drinkingUse disordersDirect acting antiviral (DAA) treatmentAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionHepatitis C virus (HCV) treatmentCox proportional hazards regressionC virus infectionC virus treatmentProportional hazards regressionTenth Revision diagnosisAUDIT-C questionnaireInternational Statistical ClassificationRelated Health ProblemsAntiviral treatmentRevision diagnosisCessation of self-reported opioid use and impacts on co-occurring health conditions
Scheidell J, Townsend T, Ban K, Caniglia E, Charles D, Edelman E, Marshall B, Gordon A, Justice A, Braithwaite R, Khan M. Cessation of self-reported opioid use and impacts on co-occurring health conditions. Drug And Alcohol Dependence 2022, 242: 109712. PMID: 36469994, PMCID: PMC10108375, DOI: 10.1016/j.drugalcdep.2022.109712.Peer-Reviewed Original ResearchConceptsOpioid useCocaine useSelf-reported opioid useBaseline opioid useCo-occurring health conditionsUnhealthy alcohol useEvidence-based interventionsLogistic regression modelsOpioid misusePrescription opioidsSelf-reported useReporting cannabisDepressive symptomsPainCannabis useAlcohol useHealth conditionsSubstance useSymptomsAnxiety symptomsSubsequent cessationCessationRegression modelsOutcomesParticipants
2020
All-cause mortality among males living with and without HIV initiating long-term opioid therapy, and its association with opioid dose, opioid interruption and other factors
Gordon K, Manhapra A, Crystal S, Dziura J, Edelman E, Skanderson M, Kerns R, Justice A, Tate J, Becker W. All-cause mortality among males living with and without HIV initiating long-term opioid therapy, and its association with opioid dose, opioid interruption and other factors. Drug And Alcohol Dependence 2020, 216: 108291. PMID: 33011662, PMCID: PMC7644145, DOI: 10.1016/j.drugalcdep.2020.108291.Peer-Reviewed Original ResearchConceptsMorphine equivalent daily doseCause mortalityLong-term opioid therapyTime-updated Cox regressionStrong dose-response relationshipUnnatural deathsEquivalent daily doseDose-response relationshipOpioid doseOpioid therapyUninfected patientsOpioid useDaily doseCox regressionMortality outcomesTherapy doseHigh doseMale veteransOverdose fatalitiesOverdose mortalityPLWHMortalityHIVPatientsDose
2016
Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. PMID: 27431048, PMCID: PMC4976086, DOI: 10.1016/j.jsat.2016.06.002.Peer-Reviewed Original ResearchConceptsLiver enzyme elevationAlcohol use disorderUninfected patientsHepatotoxic medicationsHCV infectionUse disordersComposite endpointLiver injuryHIV/HCV co-infected patientsHCV co-infected patientsHIV/HCV statusPre-existing liver injuryCo-infected patientsCohort of HIVHepatitis C infectionHIV/HCVOpioid use disorderRisk of hepatotoxicityHCV statusHepatic safetyMedian ALTC infectionChart reviewEnzyme elevationHIV infection